Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial
Titel:
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial
Auteur:
Rini, Brian I. Atkins, Michael B. Plimack, Elizabeth R. Soulières, Denis McDermott, Raymond S. Bedke, Jens Tartas, Sophie Alekseev, Boris Melichar, Bohuslav Shparyk, Yaroslav Kondoh, Chihiro Langiewicz, Przemyslaw Wood, Lori A. Hammers, Hans Silber, Cynthia G. Haber, Barbara Jensen, Erin Chen, Mei Powles, Thomas